Supplementary Table S1 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Article Swipe
Miro J. Eigenmann
,
Nicolas Frances
,
Gerhard Hoffmann
,
Thierry Lavé
,
Antje‐Christine Walz
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.22508373.v1
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.22508373.v1
Tabular representation of the experimental settings for the short- and long term experiments.
Related Topics
Concepts
Metadata
- Type
- supplementary-materials
- Language
- en
- Landing Page
- https://doi.org/10.1158/1535-7163.22508373.v1
- https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Combining_Nonclinical_Experiments_with_Translational_PKPD_Modeling_to_Differentiate_Erlotinib_and_Gefitinib/22508373/1/files/39970203.pdf
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4362638865
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4362638865Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1535-7163.22508373.v1Digital Object Identifier
- Title
-
Supplementary Table S1 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and GefitinibWork title
- Type
-
supplementary-materialsOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-04-03Full publication date if available
- Authors
-
Miro J. Eigenmann, Nicolas Frances, Gerhard Hoffmann, Thierry Lavé, Antje‐Christine WalzList of authors in order
- Landing page
-
https://doi.org/10.1158/1535-7163.22508373.v1Publisher landing page
- PDF URL
-
https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Combining_Nonclinical_Experiments_with_Translational_PKPD_Modeling_to_Differentiate_Erlotinib_and_Gefitinib/22508373/1/files/39970203.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Combining_Nonclinical_Experiments_with_Translational_PKPD_Modeling_to_Differentiate_Erlotinib_and_Gefitinib/22508373/1/files/39970203.pdfDirect OA link when available
- Concepts
-
Erlotinib, Gefitinib, Table (database), Representation (politics), Computer science, Medicine, Internal medicine, Data mining, Epidermal growth factor receptor, Political science, Receptor, Politics, LawTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4362638865 |
|---|---|
| doi | https://doi.org/10.1158/1535-7163.22508373.v1 |
| ids.doi | https://doi.org/10.1158/1535-7163.22508373.v1 |
| ids.openalex | https://openalex.org/W4362638865 |
| fwci | 0.0 |
| type | supplementary-materials |
| title | Supplementary Table S1 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10417 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9977999925613403 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Lung Cancer Treatments and Mutations |
| topics[1].id | https://openalex.org/T12334 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9645000100135803 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Lung Cancer Research Studies |
| topics[2].id | https://openalex.org/T11503 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9244999885559082 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Cytokine Signaling Pathways and Interactions |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2778087573 |
| concepts[0].level | 4 |
| concepts[0].score | 0.8675292134284973 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q418369 |
| concepts[0].display_name | Erlotinib |
| concepts[1].id | https://openalex.org/C2780580887 |
| concepts[1].level | 4 |
| concepts[1].score | 0.7990154027938843 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q417824 |
| concepts[1].display_name | Gefitinib |
| concepts[2].id | https://openalex.org/C45235069 |
| concepts[2].level | 2 |
| concepts[2].score | 0.5994970202445984 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q278425 |
| concepts[2].display_name | Table (database) |
| concepts[3].id | https://openalex.org/C2776359362 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5844615697860718 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q2145286 |
| concepts[3].display_name | Representation (politics) |
| concepts[4].id | https://openalex.org/C41008148 |
| concepts[4].level | 0 |
| concepts[4].score | 0.3770410418510437 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q21198 |
| concepts[4].display_name | Computer science |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.3031323552131653 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.23883718252182007 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C124101348 |
| concepts[7].level | 1 |
| concepts[7].score | 0.19591179490089417 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q172491 |
| concepts[7].display_name | Data mining |
| concepts[8].id | https://openalex.org/C2779438470 |
| concepts[8].level | 3 |
| concepts[8].score | 0.1289486289024353 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q424401 |
| concepts[8].display_name | Epidermal growth factor receptor |
| concepts[9].id | https://openalex.org/C17744445 |
| concepts[9].level | 0 |
| concepts[9].score | 0.06819811463356018 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q36442 |
| concepts[9].display_name | Political science |
| concepts[10].id | https://openalex.org/C170493617 |
| concepts[10].level | 2 |
| concepts[10].score | 0.058245301246643066 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[10].display_name | Receptor |
| concepts[11].id | https://openalex.org/C94625758 |
| concepts[11].level | 2 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7163 |
| concepts[11].display_name | Politics |
| concepts[12].id | https://openalex.org/C199539241 |
| concepts[12].level | 1 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q7748 |
| concepts[12].display_name | Law |
| keywords[0].id | https://openalex.org/keywords/erlotinib |
| keywords[0].score | 0.8675292134284973 |
| keywords[0].display_name | Erlotinib |
| keywords[1].id | https://openalex.org/keywords/gefitinib |
| keywords[1].score | 0.7990154027938843 |
| keywords[1].display_name | Gefitinib |
| keywords[2].id | https://openalex.org/keywords/table |
| keywords[2].score | 0.5994970202445984 |
| keywords[2].display_name | Table (database) |
| keywords[3].id | https://openalex.org/keywords/representation |
| keywords[3].score | 0.5844615697860718 |
| keywords[3].display_name | Representation (politics) |
| keywords[4].id | https://openalex.org/keywords/computer-science |
| keywords[4].score | 0.3770410418510437 |
| keywords[4].display_name | Computer science |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.3031323552131653 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.23883718252182007 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/data-mining |
| keywords[7].score | 0.19591179490089417 |
| keywords[7].display_name | Data mining |
| keywords[8].id | https://openalex.org/keywords/epidermal-growth-factor-receptor |
| keywords[8].score | 0.1289486289024353 |
| keywords[8].display_name | Epidermal growth factor receptor |
| keywords[9].id | https://openalex.org/keywords/political-science |
| keywords[9].score | 0.06819811463356018 |
| keywords[9].display_name | Political science |
| keywords[10].id | https://openalex.org/keywords/receptor |
| keywords[10].score | 0.058245301246643066 |
| keywords[10].display_name | Receptor |
| language | en |
| locations[0].id | doi:10.1158/1535-7163.22508373.v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Combining_Nonclinical_Experiments_with_Translational_PKPD_Modeling_to_Differentiate_Erlotinib_and_Gefitinib/22508373/1/files/39970203.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1535-7163.22508373.v1 |
| locations[1].id | pmh:oai:figshare.com:article/22508373 |
| locations[1].is_oa | True |
| locations[1].source.id | https://openalex.org/S4306400572 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | OPAL (Open@LaTrobe) (La Trobe University) |
| locations[1].source.host_organization | https://openalex.org/I196829312 |
| locations[1].source.host_organization_name | La Trobe University |
| locations[1].source.host_organization_lineage | https://openalex.org/I196829312 |
| locations[1].license | cc-by |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | Text |
| locations[1].license_id | https://openalex.org/licenses/cc-by |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | |
| locations[1].landing_page_url | https://figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Combining_Nonclinical_Experiments_with_Translational_PKPD_Modeling_to_Differentiate_Erlotinib_and_Gefitinib/22508373 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5023517315 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-7193-9264 |
| authorships[0].author.display_name | Miro J. Eigenmann |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Miro J. Eigenmann |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5052927788 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Nicolas Frances |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Nicolas Frances |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5111616260 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Gerhard Hoffmann |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Gerhard Hoffmann |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5044090708 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Thierry Lavé |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Thierry Lavé |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5078439299 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-2177-545X |
| authorships[4].author.display_name | Antje‐Christine Walz |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Antje-Christine Walz |
| authorships[4].is_corresponding | False |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Combining_Nonclinical_Experiments_with_Translational_PKPD_Modeling_to_Differentiate_Erlotinib_and_Gefitinib/22508373/1/files/39970203.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Supplementary Table S1 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10417 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9977999925613403 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Lung Cancer Treatments and Mutations |
| related_works | https://openalex.org/W2254126652, https://openalex.org/W2418692205, https://openalex.org/W2015104488, https://openalex.org/W3147989365, https://openalex.org/W2280113021, https://openalex.org/W2348666640, https://openalex.org/W2363852307, https://openalex.org/W2184487997, https://openalex.org/W1991551364, https://openalex.org/W2118360509 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1158/1535-7163.22508373.v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Combining_Nonclinical_Experiments_with_Translational_PKPD_Modeling_to_Differentiate_Erlotinib_and_Gefitinib/22508373/1/files/39970203.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1535-7163.22508373.v1 |
| primary_location.id | doi:10.1158/1535-7163.22508373.v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_S1_from_Combining_Nonclinical_Experiments_with_Translational_PKPD_Modeling_to_Differentiate_Erlotinib_and_Gefitinib/22508373/1/files/39970203.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1535-7163.22508373.v1 |
| publication_date | 2023-04-03 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.of | 2 |
| abstract_inverted_index.and | 9 |
| abstract_inverted_index.for | 6 |
| abstract_inverted_index.the | 3, 7 |
| abstract_inverted_index.long | 10 |
| abstract_inverted_index.term | 11 |
| abstract_inverted_index.short- | 8 |
| abstract_inverted_index.settings | 5 |
| abstract_inverted_index.experimental | 4 |
| abstract_inverted_index.representation | 1 |
| abstract_inverted_index.<p>Tabular | 0 |
| abstract_inverted_index.experiments.</p> | 12 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 5 |
| citation_normalized_percentile.value | 0.20305119 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |